Diabetes Flashcards Preview

CPT Drugs > Diabetes > Flashcards

Flashcards in Diabetes Deck (7)
Loading flashcards...
1
Q

Insulin

A

Indication: type 1 diabetic/ late stage type 2

Rapid acting = novorapid (starts 10 mins, lasts 4 hrs)
Short acting = actrapid (starts 30 mins, lasts 8hrs)
Intermediate = insulatard (starts 1hr, lasts 16hrs)
Long acting = lantus/levemir (starts 1 hr, lasts 24hr)
Combination = humalog/novomix (rapid and intermediate)

Adverse effects:
- weight gain - anabolic hormone
- hypoglycaemia
- lipodystophy (rotate site of administration)

Warning: renal impairement - hypoglycaemia risk

Interactions:
- systemic steroids - need to increase insulin dose
- other hypoglycaemic agents

Other:

  • protein so must be given paraenterally to avoid digestion
  • short half life so slow absoprtiom via soluble insulin or insulin analogues
2
Q

Metformin

A

Indication: hyperglycaemia

Class: biguanides

Hypoglycaemia: no

Weight: supress apetite

Route: oral

Action:

  • reduces hepatic glucose by inhibiting gluconeogenesis and glycogenolysis
  • decrease insulin resistance
  • increase glucose uptake in target tissues

Adverse effects:
GI upset - nausea, vomiting, diarrhoea
Lactic acidosis
B12 deficiency

Warnings:

  • stop if eGFR <30 - excreted unchanged by the kidneys so can quickly accumulate
  • alcohol intoxication

Interactions:

  • ACEi, NSAIDs, diuretics - may impair renal function
  • loop and thiazide can increase glucose so reduce metformin action

Mneumonic: BIGuanide - big liver - inhibits gluconeogenesis, big interactions

3
Q

Gliclazide

A

Indication: hyperglyceamia

Class: sulfonylureas

Hypoglycaemia: yes

Weight: increased - anabolic effecrs of insulin

Route: oral

Action: stimulate pancreatic insulin secretion by blocking ATP-dependant K+ channels

Adverse effects: GI upset

Warnings:
- hepatic and renal disease
- increased risk of CVD and MI when monotherapy

Interactions:

  • other hypoglycaemic agents
  • loop and thiazide can increase glucose so reduce SU action

Mneumonic: sulfonylureas - 3S’s - stimulate insulin secretion

4
Q

Pioglitazone/rosiglitazone

A

Indication: hypergylycaemia

Class: glitazone

Hypoglycaemia: yes

Weight: increased - fat cell differentiation

Route: oral

Action:
- enhanced insulin sensitivty and utilisation
- decreased liver production of glucose

Adverse effects:
- GI upset
- fluid retention
- fracture risk
- bladder cancer
- heart failure
- anaemia

Warnings: heart failure because of fluid retention

Interactions: other hypoglycaemic agents

Mneumonic: clitazone - insulin sensitisation, zone - transcription zone (PPAR)

5
Q

Dapagliflozin/canagliflozin

A

Indication: hyperglycaemia

Class: SGLT-2 inhibitors - used in patients with CVD

Hypoglycaemia: no

Weight: decrease

Route: oral

Actions: reduce glucose reabsorption

Adverse effects:
- UTI
- genital infection
- thirst and polyuria
- diabetic ketoacidosis
- lower limb amputation

Warnings:
- hypovolaemia - possible hypotension due to osmotic diuresis
- do not give in CKD

Interactions: antihypertensives and other hypoglycaemic agents

Mneumonic: starts with G, ends in S, flo in the middle - glucose sodium inhibitor

6
Q

Sitagliptin/saxagliptin

A

Indication: hyperglycaemia

Class: DPP-4 inhibitor

Hypoglycaemia: no

Weight: reduce apetite

Route: oral

Action: prevent incretin degradation - promote insulin secretion and supress glucagon release

Adverse effects:
- GI upset
- pancreatitis
- URTI symtpoms

Warnings:

  • pregnancy
  • pancreatitis

Interactions:

  • other hypoglycaemic agents
  • drugs which increase glucose oppose gliptin action e.g thiazides

Mneumonic: 5P’s - prevent incretin breakdown, increase plasma conc, promote insulin secretion, pancreatitis, pregnancy

7
Q

Exenatide/liraglutide/semaglutide

A

Indication: hyperglycaemia

Class: GLP-1 receptor agonist - CVD patients

Hypoglycaemia: no

Weight: weight loss

Route: SUBCUTANEOUS

Actions: increase glucose dependent synthesis of insulin

Adverse effects:
- GI upset
- decreased apetite with weight loss
- dizziness

Warnings: renal impairment

Interactions: other hypoglycaemic agents